Literature DB >> 7539218

Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma.

V E Baracos1, C DeVivo, D H Hoyle, A L Goldberg.   

Abstract

Rats implanted with Yoshida ascites hepatoma (YAH) show a rapid and selective loss of muscle protein due mainly to a marked increase (63-95%) in the rate of protein degradation (compared with rates in muscles of pair-fed controls). To define which proteolytic pathways contribute to this increase, epitrochlearis muscles from YAH-bearing and control rats were incubated under conditions that modify different proteolytic systems. Overall proteolysis in either group of rats was not affected by removal of Ca2+ or by blocking the Ca(2+)-dependent proteolytic system. Inhibition of lysosomal function with methylamine reduced proteolysis (-12%) in muscles from YAH-bearing rats, but not in muscles of pair-fed rats. When ATP production was also inhibited, the remaining accelerated proteolysis in muscles of tumor-bearing rats fell to control levels. Muscles of YAH-bearing rats showed increased levels of ubiquitin-conjugated proteins and a 27-kDa proteasome subunit in Western blot analysis. Levels of mRNA encoding components of proteolytic systems were quantitated using Northern hybridization analysis. Although their total RNA content decreased 20-38%, pale muscles of YAH-bearing rats showed increased levels of ubiquitin mRNA (590-880%) and mRNA for multiple subunits of the proteasome (100-215%). Liver, kidney, heart, and brain showed no weight loss and no change in these mRNA species. Muscles of YAH-bearing rats also showed small increases (30-40%) in mRNA for cathepsins B and D, but not for calpain I or heat shock protein 70. Our findings suggest that accelerated muscle proteolysis and muscle wasting in tumor-bearing rats result primarily from activation of the ATP-dependent pathway involving ubiquitin and the proteasome.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Substances:

Year:  1995        PMID: 7539218     DOI: 10.1152/ajpendo.1995.268.5.E996

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  85 in total

Review 1.  Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle.

Authors:  D Attaix; D Taillandier; L Combaret; C Rallière; D Larbaud; E Aurousseau; K Tanaka
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

2.  Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.

Authors:  Jie Du; Xiaonan Wang; Christiane Miereles; James L Bailey; Richard Debigare; Bin Zheng; S Russ Price; William E Mitch
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 3.  The role of the ubiquitin-proteasome system in kidney diseases.

Authors:  Hirotaka Fukasawa
Journal:  Clin Exp Nephrol       Date:  2012-06-09       Impact factor: 2.801

Review 4.  The cancer anorexia/weight loss syndrome: therapeutic challenges.

Authors:  Karin F Giordano; Aminah Jatoi
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

5.  Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles.

Authors:  N E Tawa; R Odessey; A L Goldberg
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 6.  Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks.

Authors:  Simon S Wing; Stewart H Lecker; R Thomas Jagoe
Journal:  Crit Rev Clin Lab Sci       Date:  2011-06-24       Impact factor: 6.250

Review 7.  Tearin' up my heart: proteolysis in the cardiac sarcomere.

Authors:  Andrea L Portbury; Monte S Willis; Cam Patterson
Journal:  J Biol Chem       Date:  2011-01-21       Impact factor: 5.157

8.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.

Authors:  Aminah Jatoi; Steven R Alberts; Nathan Foster; Roscoe Morton; Patrick Burch; Margaret Block; Phuong L Nguyen; John Kugler
Journal:  Support Care Cancer       Date:  2005-03-10       Impact factor: 3.603

10.  Coordinate activation of lysosomal, Ca 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle.

Authors:  D Taillandier; E Aurousseau; D Meynial-Denis; D Bechet; M Ferrara; P Cottin; A Ducastaing; X Bigard; C Y Guezennec; H P Schmid
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.